

# Test Information Sheet

GeneDx

## Spinocerebellar Ataxia and Related Disorders Panel

### DISORDER ALSO KNOWN AS

SCA, Hereditary Ataxia, Spinocerebellar Degeneration

### PANEL GENE LIST

AARS2\*, ABCD1, AFG3L2, ANO10, APTX, ATM, CACNA1A, CACNA1G\*, CLN5\*, CYP27A1, CYP7B1, C10ORF2\*, DNMT1, EEF2, ELOVL4, ELOVL5, FGF14, GNB4, GRID2, GRM1, HEXA, HEXB\*, ITPR1\*, KCNA1\*, KCNC3, KCND3, KIAA0196, KIF5A, MME, NOTCH3\*, PDYN, PEX7\*, PMM2\*, PNKP, PNPLA6, POLG, POLR3A, PRKCG, PRNP, RRM2B\*, SACS, SETX, SLC20A2, SPG7, SPG11, SPTBN2, STUB1, SYNE1, SYT14, TDP1, TGM6, TMEM240\*\*, TPP1\*, TTBK2, TTPA, ZFYVE26

\* Sequence analysis only of the AARS2, CACNA1G, CLN5, C10ORF2, HEXB, ITPR1, KCNA1, NOTCH3, PEX7, PMM2, RRM2B, and TPP1 genes

\*\* Only whole gene deletions or duplications may be detected for TMEM240 gene

### CLINICAL FEATURES

The Spinocerebellar Ataxias (SCAs) are a clinically and genetically heterogeneous group of neurodegenerative disorders characterized by progressive incoordination of movements. Clinical features include uncoordinated gait and hand movements, dysarthria, dysphagia, nystagmus and are usually associated with atrophy of the cerebellum.<sup>1</sup> In addition to ataxia, the disorders evaluated on this panel can also present with oculomotor apraxia and/or spastic paraplegia. Oculomotor apraxia (abnormal horizontal eye movement) may also be present with myoclonus, dystonia, and/or neuropathy.<sup>2,3</sup> Spastic paraplegia, characterized by lower limb spasticity and muscle weakness, can also be seen with decreased vibration sense, optic atrophy, hyperreflexia, and neuropathy.<sup>4</sup> Also included on this panel are episodic ataxias that often present as periods of unsteady gait with or without myokymia, which may result in permanent ataxia late in disease course.<sup>1</sup> Although considerable phenotypic overlap exists between the SCAs and related disorders, distinguishing features have been noted in most subtypes.<sup>1,2,4,5</sup> The SCAs are typically classified based on mode of inheritance, age of onset and clinical features. Age of onset ranges from the 3rd to 4th decades of life, although some disorders can present as early as childhood.<sup>5</sup> Treatment is primarily supportive for most forms of inherited SCA.<sup>1</sup> The prevalence of autosomal dominant and autosomal recessive cerebellar ataxia, including individuals with polynucleotide repeat disorders, is estimated to be approximately 1-5:100,000 and 3:100,000 individuals in the general population, respectively.<sup>1,6</sup>

### INHERITANCE PATTERN/GENETICS

Ataxias can be either genetic or acquired in nature. Acquired ataxia may be the result of alcoholism, vitamin deficiency, multiple sclerosis, vascular disease, metastatic cancer, or paraneoplastic diseases.<sup>1,7</sup> Genetic forms may display autosomal dominant, autosomal recessive, X-linked, or mitochondrial inheritance.<sup>1,5</sup> The hereditary ataxias, especially adult onset forms, can be difficult to differentiate by clinical evaluation alone due to similarities in early manifestations and overlapping ages of onset.<sup>1</sup> Often, molecular genetic testing can assist in diagnosis, when combined with family history, physical examination and neuroimaging. Approximately 50% of ataxia is attributed to pathogenic repeat expansions in a small subset of genes, an additional 20% is attributed to pathogenic sequence based changes, in a larger number of genes and the remaining causes are acquired or undetermined.<sup>8,9</sup> The Spinocerebellar Ataxia and Related Disorders Panel at GeneDx includes sequencing and deletion/duplication analysis of genes associated with autosomal dominant and recessive disorders, excluding repeat expansion related disorders. The genes on this panel mostly code for ion channels transporters, mitochondrial and cell membrane proteins, and proteins involved in DNA repair and RNA/protein processing.<sup>10</sup> The complete list of genes, inheritances, and associated disorders is included in the table below.

### TEST METHODS

Genomic DNA is extracted from the submitted specimen. For skin punch biopsies, fibroblasts are cultured and used for DNA extraction. The DNA is enriched for the complete coding regions and splice site junctions of the

# Test Information Sheet

GeneDx

genes on this panel using a proprietary targeted capture system developed by GeneDx for next-generation sequencing with CNV calling (NGS-CNV). The enriched targets are simultaneously sequenced with paired-end reads on an Illumina platform. Bi-directional sequence reads are assembled and aligned to reference sequences based on NCBI RefSeq transcripts and human genome build GRCh37/UCSC hg19. After gene specific filtering, data are analyzed to identify sequence variants and most deletions and duplications involving coding exons at the exon-level; however, technical limitations and inherent sequence properties effectively reduce this resolution for some genes. For the *AARS2*, *CACNA1G*, *CLN5*, *C10ORF2*, *HEXB*, *ITPR1*, *KCNA1*, *NOTCH3*, *PEX7*, *PMM2*, *RRM2B*, and *TPP1* genes, sequencing but not deletion/duplication analysis are performed. For the *TMEM240* gene, only whole gene CNVs are reported. Alternative sequencing or copy number detection methods are used to analyze regions with inadequate sequence or copy number data by NGS. Sequence variants are reported according to the Human Genome Variation Society (HGVS) guidelines. Copy number variants are reported based on the probe coordinates, the coordinates of the exons involved, or precise breakpoints when known. Reportable variants include pathogenic variants, likely pathogenic variants, and variants of uncertain significance. Likely benign and benign variants, if present, are not routinely reported but are available upon request. Available evidence for variant classification may change over time and the reported variant(s) may be re-classified according to the AMP/ACMG guidelines for variant classification (Richards et al. 2015), which may lead to re-issuing a revised report.

The technical sensitivity of sequencing is estimated to be >99% at detecting single nucleotide events, but less for deletions greater than 20 base pairs, insertions or rearrangements greater than 10 base pairs, or low-level mosaicism. The copy number assessment methods used with this test identify most deletions and duplications involving coding exons but are less reliable for detecting copy number variants of less than 500 base pairs. Assessment of copy number events also depends on the inherent sequence properties of the targeted regions, including shared homology and exon size. Mosaicism detection is limited and balanced chromosome aberrations cannot be identified.

## TEST SENSITIVITY

In a clinically heterogeneous cohort of individuals with ataxia, Nemeth et al. (2013) identified a pathogenic single nucleotide variant in 8.3% of individuals with adult onset ataxia and 40% of individuals with childhood onset ataxia, who previously had a negative result for a panel of common polynucleotide repeat expansion disorders.

## Spinocerebellar Ataxia and Related Disorders Panel

Gene	Disease Associations	Inheritance	Diagnostic Yield in Selected Population(s)
<i>AARS2</i> **	Leukoencephalopathy with ovarian failure	AR	Rare <sup>1,10</sup>
<i>ABCD1</i>	Adrenoleukodystrophy	XR	Rare in ataxia <sup>34</sup>
<i>AFG3L2</i>	SCA28	AD	~1.5% of AD cerebellar ataxia <sup>11</sup>
<i>ANO10</i>	SCA10	AR	Common in Mexican and Brazilian populations <sup>12</sup>
<i>APTX</i>	AOA1	AR	4-9% of AR ataxia <sup>13</sup>
<i>ATM</i>	Ataxia-telangiectasia	AD/AR	1:40,000-1:100,000 in US, Common cause of child onset cerebellar ataxia <sup>14</sup>
<i>CACNA1A</i> *	Episodic ataxia type 2 (EA2); familial hemiplegic migraine (FHM); spinocerebellar ataxia type 6 (SCA6)	AD	EA2 is rare form of ataxia <sup>15-17</sup>

# Test Information Sheet

<i>CACNA1G*</i>	SCA42	AD	Recurrent variant identified in specific populations <sup>35</sup>
<i>CLN5**</i>	Adult-onset AR ataxia associated with neuronal ceroid-lipofuscinosis 5	AR	Rare <sup>1,10</sup>
<i>CYP27A1</i>	Cerebrotendinous xanthomatosis	AR	Rare in ataxia <sup>1,10</sup> ; Treatment options available <sup>36</sup>
<i>CYP7B1</i>	Spastic paraparesis 5A	AR	Rare cause of sensory ataxia <sup>37</sup>
<i>C100RF2**</i>	Perrault syndrome 5; Progressive external ophthalmoplegia with mitochondrial DNA deletions	AR	Rare <sup>1,10</sup>
<i>DNMT1</i>	Cerebellar ataxia, deafness, and narcolepsy; hereditary sensory neuropathy type IE	AD	Rare <sup>1,18</sup>
<i>EEF2</i>	SCA26	AD	Rare <sup>1,10,38</sup>
<i>ELOVL4</i>	SCA34	AD	Rare <sup>1,10,19</sup>
<i>ELOVL5</i>	SCA28	AD	Rare <sup>1,20</sup>
<i>FGF14</i>	SCA27	AD	Rare <sup>21,22</sup>
<i>GNB4</i>	Charcot-Marie-Tooth disease	AD	Rare in ataxia <sup>1,10,39</sup>
<i>GRID2</i>	SCA18	AD/AR	Rarely AD <sup>40</sup>
<i>GRM1</i>	SCA44; SCAR13	AR/AR	Rare <sup>23,24</sup>
<i>HEXA</i>	Tay-Sachs disease	AR	Rare in ataxia <sup>25</sup>
<i>HEXB**</i>	Sandhoff disease	AR	Rare in ataxia <sup>26</sup>
<i>ITPR1**</i>	SCA15; SCA16; SCA29; Gillespie syndrome	AD/AR	2-3% of familial ataxia in Australian populations <sup>1,10,27</sup>
<i>KCNA1**</i>	Episodic ataxiatype 1 (EA1)	AD	Rare <sup>1,10</sup>
<i>KCNC3</i>	SCA13	AD	Rare <sup>1,10</sup>
<i>KCND3</i>	SCA19; SCA22	AD	Rare <sup>1,10</sup>
<i>KIAA0196</i>	Spastic paraparesis 8	AD	Rare <sup>10</sup>
<i>KIF5A</i>	Spastic paraparesis 10	AD	Rare in ataxia <sup>41</sup>
<i>MME</i>	SCA43	AD/AR	Rare <sup>42</sup>
<i>NOTCH3**</i>	Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1 (CADASIL)	AD	Rare in ataxia <sup>43</sup>
<i>PDYN</i>	SCA23	AD	Rare <sup>1,10</sup>
<i>PMM2**</i>	Peroxisome biogenesis disorder (REFSUM)	AR	Rare in ataxia <sup>44</sup>
<i>PNKP</i>	Congenital disorder of glycosylationtype Ia	AR	Rare in ataxia <sup>28</sup>
<i>PNPLA6</i>	AOA4	AR	Rare <sup>1,10</sup>
<i>POLG</i>	Spastic paraparesis 39; Boucher-Neuhäuser syndrome	AR	Rare in ataxia <sup>1,30</sup>
<i>POLR3A</i>	POLG-related disorders	AR/AD	~3% of spastic ataxia <sup>45</sup>

# Test Information Sheet

GeneDx

<i>PRKCG</i>	Spastic ataxia	AR	Rare <sup>1,10</sup>
<i>PRNP</i>	SCA14	AD	Gait ataxia present in >50% of prionopathies <sup>46</sup>
<i>RRM2B**</i>	Progressive external ophthalmoplegia with mitochondrial DNA deletions	AD/AR	Rare in ataxia <sup>1,10</sup>
<i>SACS</i>	Autosomal recessive spastic ataxia of Charlevoix-S aguenay (ARSACS)	AR	Rare <sup>1,10</sup>
<i>SETX</i>	AOA2	AR	Rare <sup>1,10</sup>
<i>SLC20A2</i>	Basal ganglia calcification, idiopathic	AD	Rare <sup>10</sup>
<i>SPG7</i>	Spastic paraplegia 7	AD/AR	Rare in ataxia <sup>1,10,31</sup>
<i>SPG11</i>	SPG11 related neurodegenerative disorders	AR	Rare in ataxia <sup>10</sup>
<i>SPTBN2</i>	SCA5 (Lincoln's Ataxia); SCAR14	AD/AR	Rare <sup>1,10</sup>
<i>STUB1</i>	SCAR16	AR	Rare <sup>1,10</sup>
<i>SYNE1</i>	SYNE1-related autosomal recessive cerebellar ataxia	AR	5-6% of adult onset AR ataxias <sup>32</sup>
<i>SYT14</i>	SCA11	AD	Rare <sup>47</sup>
<i>TDP1</i>	SCA with axonal neuropathy	AR	Rare <sup>48</sup>
<i>TGM6</i>	SCA35	AD	Rare <sup>1,10</sup>
<i>TMEM240**</i>	SCA21	AD	Rare <sup>1,10,33</sup>
<i>TPP1**</i>	SCAR7; Late-infantile neuronal ceroid-lipofuscinosis 2 (CLN2)	AR	Rare inataxia <sup>1,10</sup>
<i>TTBK2</i>	SCA11	AD	Rare <sup>1,10</sup>
<i>TTPA</i>	Ataxia with vitamin E deficiency (AVED)	AR	Rare <sup>1,10</sup>
<i>ZFYVE26</i>	Spastic paraplegia 15	AR	Rare <sup>10</sup>

\*The CAG repeat expansion in *CACNA1A* that causes SCA6 is not detectable by this test.

\*\*Does not include deletion/duplication testing of *AARS2*, *CACNA1G*, *CLN5*, *C10ORF2*, *HEXB*, *ITPR1*, *KCNA1*, *NOTCH3*, *PEX7*, *PMM2*, *RRM2B*, and *TPP1*.

\*\*\*Only whole gene deletions or duplications of be detected.

## Abbreviations:

AD – Autosomal Dominant

AR – Autosomal Recessive

XR – X-linked recessive

SCA – Spinocerebellar Ataxia

AOA – Ataxia with Oculomotor Apraxia

SCAR – Autosomal Recessive Spinocerebellar Ataxia

## REFERENCES:

- Bird TD. Hereditary Ataxia Overview. 1998 Oct 28 [Updated 2019 Apr 18]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK1138/>; (PMID: 20301317)
- Coutinho et al. (1993) Ataxia with Oculomotor Apraxia Type 1. 2002 Jun 11 [Updated 2015 Mar 19]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK1456/>; (PMID: 20301629)

# Test Information Sheet

GeneDx

3. Adam et al. (1993) Ataxia with Oculomotor Apraxia Type 2. 2004 Nov 15 [Updated 2018 Jul 12]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK1154/>; (PMID: 20301333)
4. Hedera et al. (1993) Hereditary Spastic Paraparesis Overview. 2000 Aug 15 [Updated 2018 Sep 27]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK1509/>; (PMID: 20301682)
5. Jayadev S and Bir d TD.( 2013) Hereditary ataxias: overview. Genetics In Medicine : Official Journal Of The American College Of Medical Genetics. 15(9):673-83.23538602. (PMID: 23538602)
6. Ruano L et al. (2014) The global epidemiology of hereditary ataxia and spastic paraparesis: a systematic review of prevalence studies. Neuroepidemiology.42(3):174-83.24603320. (PMID: 24603320)
7. Barsottini OG et al., 2014 Adult onset sporadic ataxias: a diagnostic challenge. Arq Neuropsiquiatr 72(3):232-40. (PMID:24676442)
8. Fogel BL et al. (2014) Exome Sequencing in the Clinical Diagnosis of Sporadic or Familial Cerebellar Ataxia. JAMA Neurol. 72(1):128 (PMID: 25133958)
9. Németh AH et al. (2013) Next generation sequencing for molecular diagnosis of neurological disorders using ataxias as a model. Brain. 136(Pt 10):3106-18. (PMID: 24030952)
10. Online Mendelian Inheritance in Man, OMIM. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD). World Wide Web URL: <https://omim.org/>
11. Brussino A, Brusco A, Durr A, et al. Spinocerebellar Ataxia Type 28. 2011 May 17 [Updated 2018 Mar 22]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews [Internet]. Copyright, Seattle (WA): University of Washington, Seattle; 1993-2019. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK54582/>
12. Matsuura T, Ashizawa T. Spinocerebellar Ataxia Type 10. 2002 Apr 23 [Updated 2012 Sep 20]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews [Internet]. Copyright, Seattle (WA): University of Washington, Seattle; 1993-2019. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK1175/>
13. Coutinho P, Barbot C. (Updated March 2015) Ataxia with Oculomotor Apraxia Type 1. In: GeneReviews (database online). Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews [Internet]. Copyright, Seattle (WA): University of Washington,Seattle; 1993-2019. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK1456/>
14. Gatti R, Perlman S. Ataxia-Telangiectasia. 1999 Mar 19 [Updated 2016 Oct 27]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK26468/>
15. Spacey S. Episodic Ataxia Type 2. 2003 Feb 24 [Updated 2015 Oct 15]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews [Internet]. Copyright, Seattle (WA): University of Washington, Seattle; 1993-2019. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK1501/>
16. Jen JC. (Updated May 2015). Familial Hemiplegic Migraine. In: GeneReviews (database online). Ada m MP, Ardinger HH, Pagon RA, et a l., editors. Copyright, University of Washington, Seattle. 1993-2018. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK1388/>
17. Gomez CM. Spinocerebellar Ataxia Type 6. 1998 Oct 23 [Updated 2013 Jul 18]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews [Internet].Copyright, Seattle (WA): University of Washington, Seattle; 1993-2019. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK1140/>
18. Klein CJ. DNMT1-Related Disorder. 2012 Feb 16 [Updated 2019 Jan 31]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews [Internet]. Copyright, Seattle (WA): University of Washington, Seattle; 1993-2019. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK84112/>
19. Cadieux-Dion M et al. Expanding the clinical phenotype associated with ELOVL4 mutation: study of a large French-Canadian family with autosomal dominant spinocerebellar ataxia and erythrokeratoderma. Jama Neurology. 2014 71(4):470-5. (PMID:24566826)
20. Di Gregorio E et al. ELOVL5 mutations cause spinocerebellar ataxia 38. American Journal Of Human Genetics. 2014 Aug 7 95(2):209-17. (PMID: 25065913)
21. van Swieten JC et al. A mutation in the fibroblast growth factor 14 gene is associated with autosomal dominant cerebellar ataxia [corrected]. American Journal Of Human Genetics. 2003 Jan 72(1):191-9. (PMID: 12489043)
22. Brusse E et al. Spinocerebellar ataxia associated with a mutation in the fibroblast growth factor 14 gene (SCA27): A new phenotype. Movement Disorders : Official Journal Of The Movement Disorder Society. 2006 Mar 21(3):396-401. (PMID: 16211615)
23. Watson LM et al. Dominant Mutations in GRM1 Cause Spinocerebellar Ataxia Type 44. American Journal Of Human Genetics. 2017 Sep 07 101(3):451-458. (PMID: 28886343)
24. Guergueltcheva V et al. Autosomal-recessive congenital cerebellar ataxia is caused by mutations in metabotropic glutamate receptor 1. American Journal Of Human Genetics. 2012 Sep 7 91(3):553-64. (PMID: 22901947)
25. Kaback MM, Desnick RJ. Hexosaminidase A Deficiency. 1999 Mar 11 [Updated 2011 Aug 11]. In: Adam MP, Ardinger HH, Pagon RA, et a l., editors. GeneReviews [Internet]. Copyright, Seattle (WA): University of Washington, Seattle; 1993-2019. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK1218/>
26. Brown CA et al. Characterization of two HEXB gene mutations in Argentinean patients with Sandhoff disease. Biochimica Et Biophysica Acta. 1992 1180(1):91-8. (PMID: 1390948)
27. Storey E. Spinocerebellar Ataxia Type 15. 2006 May 30 [Updated 2014 Jun 12]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews [Internet]. Copyright, Seattle (WA): University of Washington, Seattle; 1993-2019. Available at:<https://www.ncbi.nlm.nih.gov/books/NBK1362/>
28. Sparks SE, Krasnewich DM. PMM2-CDG (CDG-Ia) 2005 Aug 15 [Updated 2015 Oct 29]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews [Internet]. Copyright, Seattle (WA): University of Washington, Seattle; 1993-2019. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK1110/>
29. Bras J et al. Mutations in PNKP cause recessive ataxia with oculomotor apraxia type 4. American Journal Of Human Genetics. 2015 Mar 5 96(3):474-9. (PMID: 25728773)
30. Cohen BH, Chinnery PF, Copeland WC. POLG-Related Disorders. 2010 Mar 16 [Updated 2018 Mar 1]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews [Internet]. Copyright, Seattle (WA): University of Washington, Seattle; 1993-2019. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK26471/>
31. Casari G, Marconi R. Spastic Paraparesis 7. 2006 Aug 24 [Updated 2018 Oct 25]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews [Internet]. Copyright, Seattle (WA): University of Washington, Seattle; 1993-2019. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK1107/>
32. Beaudin M, Gamache PL, Gros-Louis F, et al. SYNE1 Deficiency. 2007 Feb 23 [Updated 2018 Dec 6]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews [Internet]. Copyright, Seattle (WA): University of Washington, Seattle; 1993-2019. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK1379/>

# Test Information Sheet

GeneDx

33. Delplanque J et al. TMEM240 mutations cause spinocerebellar ataxia 21 with mental retardation and severe cognitive impairment. *Brain : A Journal Of Neurology.* 2014 Oct 137(Pt 10):2657-63. (PMID: 25070513)
34. Chen YH et al. Unmasking adrenoleukodystrophy in a cohort of cerebellar ataxia. *Plo S One.* 2017 12(5):e0177296.28481932
35. Coutelier et al. (2015) Am. J. Hum. Genet. 97 (5):726-37 (PMID: 26456284)
36. Cao LX et al. Chinese patient with cerebrotendinous xanthomatosis confirmed by genetic testing: A case report and literature review. *World Journal Of Clinical Cases.* 2020 Nov 06 8(21):5446-5456.33269283
37. Di Fabio R et al. Sensory ataxia as a prominent clinical presentation in three families with mutations in CYP7B1. *Journal Of Neurology.* 2014 Apr 261(4):747-51.24519355
38. Hekman et al. (2012) *Hum. Mol. Genet.* 21 (26):5472-83 (PMID: 23001565)
39. Bird TD. Charcot-Marie-Tooth (CMT) Hereditary Neuropathy Overview. Seattle (WA): University of Washington, Seattle; 1993-2019.(Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1358/>).20301532
40. Coutelier et al. (2015) *Neurology* 84 (17):1751-9 (PMID: 25841024)
41. Brenner D and Weishaupt JH. Update on amyotrophic lateral sclerosis genetics. *Current Opinion In Neurology.* 2019 10 32(5):735-739.31335339
42. Depondt et al. (2016) *Neurol Genet* 2 (5):e94 (PMID: 27583304)
43. Park DG et al. Ataxia Associated with CADASIL: a Pathology-Confirmed Case Report and Literature Review. *Cerebellum (London, England).* 2020 Dec 19(6):907-910.32734377
44. Nanetti L et al. PEX7 Mutations Cause Congenital Cataract Retinopathy and Late-Onset Ataxia and Cognitive Impairment: Report of Two Siblings and Review of the Literature. *Journal Of Clinical Neurology (Seoul, Korea).* 2015 Apr 11(2):197-9.25851898
45. Minnerop M et al. Hypomorphic mutations in POLR3A are a frequent cause of sporadic and recessive spastic ataxia. *Brain : A Journal Of Neurology.* 2017 Jun 01 140(6):1561-1578.28459997
46. Rodriguez-Porcel F et al. Movement Disorders in Prionopathies: A Systematic Review. *Tremor And Other Hyperkinetic Movements (New York, N.Y.).* 2019 9.31871824
47. Doi H et al. Exome sequencing reveals a homozygous SYT14 mutation in adult-onset, autosomal-recessive spinocerebellar ataxia with psychomotor retardation. *American Journal Of Human Genetics.* 2011 Aug 12 89(2):320-7.21835308
48. Scott P et al. Spinocerebellar ataxia with axonal neuropathy type 1 revisited. *Journal Of Clinical Neuroscience : Official Journal Of The Neurosurgical Society Of Australasia.* 2019 Sep 67:139-144.31182267